Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California. more
Time Frame | ATYR | Sector | S&P500 |
---|---|---|---|
1-Week Return | -0.63% | -3.39% | -3.47% |
1-Month Return | 4.65% | -3.25% | -0.29% |
3-Month Return | 73.08% | -11.61% | 4.5% |
6-Month Return | 90.91% | -5.89% | 6.91% |
1-Year Return | 148.03% | 2.65% | 23.79% |
3-Year Return | -60.33% | 0.56% | 28.43% |
5-Year Return | -20.45% | 34.63% | 83.64% |
10-Year Return | -98.49% | 94.78% | 185.94% |
Dec '20 | Dec '21 | Dec '22 | Dec '23 | |||
---|---|---|---|---|---|---|
Total Revenue | 10.46M | - | 10.39M | 353.00K | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":99.34,"profit":true},{"date":"2023-12-31","value":3.38,"profit":true}] | |
Cost of Revenue | 17.29M | 1.30M | 1.70M | 2.74M | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":7.54,"profit":true},{"date":"2022-12-31","value":9.8,"profit":true},{"date":"2023-12-31","value":15.85,"profit":true}] | |
Gross Profit | (6.84M) | (1.30M) | 8.69M | (2.39M) | [{"date":"2020-12-31","value":-78.66,"profit":false},{"date":"2021-12-31","value":-15,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-27.48,"profit":false}] | |
Gross Margin | (65.38%) | (Infinity%) | 83.68% | (676.49%) | [{"date":"2020-12-31","value":-78.14,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-808.42,"profit":false}] | |
Operating Expenses | 25.10M | 32.71M | 55.09M | 55.27M | [{"date":"2020-12-31","value":45.41,"profit":true},{"date":"2021-12-31","value":59.18,"profit":true},{"date":"2022-12-31","value":99.68,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |
Operating Income | (15.91M) | (34.02M) | (46.40M) | (54.92M) | [{"date":"2020-12-31","value":-1591100000,"profit":false},{"date":"2021-12-31","value":-3401500000,"profit":false},{"date":"2022-12-31","value":-4640400000,"profit":false},{"date":"2023-12-31","value":-5491900000,"profit":false}] | |
Total Non-Operating Income/Expense | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Pre-Tax Income | (16.23M) | (33.78M) | (45.34M) | (50.40M) | [{"date":"2020-12-31","value":-1623000000,"profit":false},{"date":"2021-12-31","value":-3377700000,"profit":false},{"date":"2022-12-31","value":-4534300000,"profit":false},{"date":"2023-12-31","value":-5039700000,"profit":false}] | |
Income Taxes | (6.00K) | (9.00K) | (5.00K) | (8.00K) | [{"date":"2020-12-31","value":-600000,"profit":false},{"date":"2021-12-31","value":-900000,"profit":false},{"date":"2022-12-31","value":-500000,"profit":false},{"date":"2023-12-31","value":-800000,"profit":false}] | |
Income After Taxes | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Income From Continuous Operations | (16.23M) | (33.78M) | (45.34M) | (50.40M) | [{"date":"2020-12-31","value":-1623000000,"profit":false},{"date":"2021-12-31","value":-3377700000,"profit":false},{"date":"2022-12-31","value":-4534300000,"profit":false},{"date":"2023-12-31","value":-5039700000,"profit":false}] | |
Income From Discontinued Operations | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Net Income | (16.22M) | (33.77M) | (45.34M) | (50.39M) | [{"date":"2020-12-31","value":-1622400000,"profit":false},{"date":"2021-12-31","value":-3376800000,"profit":false},{"date":"2022-12-31","value":-4533800000,"profit":false},{"date":"2023-12-31","value":-5038900000,"profit":false}] | |
EPS (Diluted) | (1.58) | (1.88) | (1.60) | (0.96) | [{"date":"2020-12-31","value":-158.46,"profit":false},{"date":"2021-12-31","value":-188.15,"profit":false},{"date":"2022-12-31","value":-159.99,"profit":false},{"date":"2023-12-31","value":-95.89,"profit":false}] | |
These ratios help you determine the liquidity of the company. Higher is better.
ATYR | |
---|---|
Cash Ratio | 4.67 |
Current Ratio | 5.41 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ATYR | |
---|---|
ROA (LTM) | -32.74% |
ROE (LTM) | -61.76% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ATYR | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.29 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.71 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ATYR | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 244.92 |
P/B | 1.76 |
Price/FCF | NM |
EV/R | 135.00 |
EV/Ebitda | NM |
aTyr Pharma, Inc. (ATYR) share price today is $3.124
Yes, Indians can buy shares of aTyr Pharma, Inc. (ATYR) on Vested. To buy aTyr Pharma, Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ATYR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of aTyr Pharma, Inc. (ATYR) via the Vested app. You can start investing in aTyr Pharma, Inc. (ATYR) with a minimum investment of $1.
You can invest in shares of aTyr Pharma, Inc. (ATYR) via Vested in three simple steps:
The 52-week high price of aTyr Pharma, Inc. (ATYR) is $3.8. The 52-week low price of aTyr Pharma, Inc. (ATYR) is $1.34.
The price-to-earnings (P/E) ratio of aTyr Pharma, Inc. (ATYR) is
The price-to-book (P/B) ratio of aTyr Pharma, Inc. (ATYR) is 1.76
The dividend yield of aTyr Pharma, Inc. (ATYR) is 0.00%
The market capitalization of aTyr Pharma, Inc. (ATYR) is $144.01M
The stock symbol (or ticker) of aTyr Pharma, Inc. is ATYR